Multiple Myeloma Research Consortium Presents New Data Affirming Success in Accelerating Drug Development Timelines

Published: Dec 14, 2011

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today presented compelling new results highlighting its success in accelerating the completion of clinical trials and the development of treatments for multiple myeloma, an incurable, but treatable blood cancer. In an oral presentation entitled, “The Multiple Myeloma Research Consortium (MMRC): Accelerated Start Up and Accrual Metrics Speeds Drug Development,” the MMRC unveiled data demonstrating improvements in trial start-up and enrollment times as well as patient accrual for clinical trials run through the Consortium.

Back to news